Real-World Treatment Patterns and Outcomes in Previously Untreated Mantle Cell Lymphoma: Findings From a Retrospective Study

2021 ◽  
Keyword(s):  
Retrospective Study ◽  
Mantle Cell Lymphoma ◽  
Real World ◽  
Cell Lymphoma ◽  
Treatment Patterns ◽  
Mantle Cell

scholarly journals REAL WORLD OUTCOME IN MANTLE CELL LYMPHOMA: A FRENCH RETROSPECTIVE STUDY IN ELDERLY PATIENTS BETWEEN 2005 AND 2018

2021 ◽  
Vol 39 (S2) ◽  
Author(s):  
B Branco ◽  
P Bories ◽  
L Ysebaert ◽  
C Laurent ◽  
B Cabarrou ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Elderly Patients ◽  
Mantle Cell Lymphoma ◽  
Real World ◽  
Cell Lymphoma ◽  
Mantle Cell

scholarly journals Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients Managed at Chinese Academic Centers in the Rituximab Era: A Real-World Study

2022 ◽  
Vol 11 ◽  
Author(s):  
Meng Wu ◽  
Yun Li ◽  
Huiqiang Huang ◽  
Wei Xu ◽  
Yanyan Wang ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Real World ◽  
Initial Treatment ◽  
Cell Lymphoma ◽  
Treatment Patterns ◽  
High Dose ◽  
First Line ◽  
Mantle Cell ◽  
High Dose Cytarabine ◽  
Ecog Ps

PurposeThe aim of the study was to delineate the disease characteristics, the initial treatment patterns, and survival in patients with mantle cell lymphoma (MCL) managed in the real world.MethodsData of 518 MCL patients from 5 major Chinese Hematology Centers in the period from 2007 to 2017 were retrospectively analyzed.ResultsThe median age was 58 years. Of the patients, 88.6% had Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0–1 and 80.7% had advanced-stage disease. Ki67 expression was <30% in 39.6% of the patients, and 43.2% of patients were categorized into a low-risk group based on the Mantle Cell Lymphoma International Prognostic Index (MIPI) scoring system. Overall, 73.4% of the patients received rituximab as their first-line therapy. The most commonly used chemotherapy was the CHOP-like (cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone) regimen (45.2%), followed by high-dose cytarabine-containing chemotherapy (31.3%) and bendamustine (3.3%). Of the patients, 13.7% (n = 71) underwent consolidative autologous stem cell transplantation (ASCT), and 19.3% (n = 100) received novel agents containing first-line regimens. With a median follow-up time of 52 months, the 3- and 5-year overall survival (OS) rates were 73.7% and 61.4%, respectively. Age ≤60 years, ECOG PS 0–1, stages I–II, normal lactate dehydrogenase (LDH), absence of bone marrow involvement, Ki67 <30%, and lower-risk IPI/MIPI scores were significantly associated with improved OS (p < 0.05). The inclusion of rituximab improved the 5-year OS, with borderline significance (62.5% vs. 55.2%, p = 0.076). High-dose cytarabine-containing chemotherapy showed significant clinical benefit in 5-year OS (72.1% vs. 55.9%, p = 0.010). Patients with ASCT had better 5-year OS in the younger (≤60 years) age group (87.2% vs. 64.8%, p = 0.002).ConclusionThis large retrospective dataset unequivocally confirmed the survival advantage afforded by cytarabine-containing regimen and ASCT in a first-line setting under real-world management in the rituximab era.

scholarly journals Erratum on “Non-indolent mantle cell lymphoma at a single public hospital in Brazil: real world first-line treatment cohort study data”

2020 ◽  
Vol 42 (2) ◽  
pp. 194
Author(s):  
Sergio Augusto Buzian Brasil ◽  
Carolina Colaço ◽  
Tomas Barrese ◽  
Roberto P. Paes ◽  
Cristina Bortolheiro ◽  
...  
Keyword(s):  
Cohort Study ◽  
Mantle Cell Lymphoma ◽  
Real World ◽  
Public Hospital ◽  
Cell Lymphoma ◽  
Study Data ◽  
Line Treatment ◽  
First Line ◽  
Mantle Cell ◽  
First Line Treatment

scholarly journals 259O Treatment patterns and outcomes in older patients with mantle cell lymphoma in an Asian population

2020 ◽  
Vol 31 ◽  
pp. S1344
Author(s):  
X. Yang ◽  
L.P. Khoo ◽  
E.W.Y. Chang ◽  
V.S. Yang ◽  
E.Y.L. Poon ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Older Patients ◽  
Cell Lymphoma ◽  
Asian Population ◽  
Treatment Patterns ◽  
Mantle Cell
Sign in / Sign up

Export Citation Format

Share Document